PATH vs SPRO
Uipath Inc (PATH) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the PATH and SPRO stock pages for the full models.
Not investment advice.